223 related articles for article (PubMed ID: 20153385)
1. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers.
Patlolla RR; Chougule M; Patel AR; Jackson T; Tata PN; Singh M
J Control Release; 2010 Jun; 144(2):233-41. PubMed ID: 20153385
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel.
Patel AR; Chougule MB; I T; Patlolla R; Wang G; Singh M
Pharm Res; 2013 May; 30(5):1435-46. PubMed ID: 23361589
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
Fulzele SV; Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2006 Mar; 58(3):327-36. PubMed ID: 16536899
[TBL] [Abstract][Full Text] [Related]
4. Fabrication, characterization and optimization of nanostructured lipid carrier formulations using Beclomethasone dipropionate for pulmonary drug delivery via medical nebulizers.
Khan I; Hussein S; Houacine C; Khan Sadozai S; Islam Y; Bnyan R; Elhissi A; Yousaf S
Int J Pharm; 2021 Apr; 598():120376. PubMed ID: 33617949
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
[TBL] [Abstract][Full Text] [Related]
6. Dermal microdialysis technique to evaluate the trafficking of surface-modified lipid nanoparticles upon topical application.
Desai PR; Shah PP; Patlolla RR; Singh M
Pharm Res; 2012 Sep; 29(9):2587-600. PubMed ID: 22644591
[TBL] [Abstract][Full Text] [Related]
7. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.
Fulzele SV; Chatterjee A; Shaik MS; Jackson T; Singh M
Pharm Res; 2006 Sep; 23(9):2094-106. PubMed ID: 16902813
[TBL] [Abstract][Full Text] [Related]
8. Preparation and evaluation of celecoxib-loaded proliposomes with high lipid content.
Jeon D; Kim KT; Baek MJ; Kim DH; Lee JY; Kim DD
Eur J Pharm Biopharm; 2019 Aug; 141():139-148. PubMed ID: 31150807
[TBL] [Abstract][Full Text] [Related]
9. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
Khan S; Baboota S; Ali J; Narang RS; Narang JK
Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
[TBL] [Abstract][Full Text] [Related]
10. Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance.
Patil-Gadhe A; Kyadarkunte A; Patole M; Pokharkar V
Eur J Pharm Biopharm; 2014 Sep; 88(1):169-77. PubMed ID: 25078860
[TBL] [Abstract][Full Text] [Related]
11. Design and evaluation of lipoprotein resembling curcumin-encapsulated protein-free nanostructured lipid carrier for brain targeting.
Meng F; Asghar S; Xu Y; Wang J; Jin X; Wang Z; Wang J; Ping Q; Zhou J; Xiao Y
Int J Pharm; 2016 Jun; 506(1-2):46-56. PubMed ID: 27094357
[TBL] [Abstract][Full Text] [Related]
12. QbD guided early pharmaceutical development study: Production of lipid nanoparticles by high pressure homogenization for skin cancer treatment.
Amasya G; Aksu B; Badilli U; Onay-Besikci A; Tarimci N
Int J Pharm; 2019 May; 563():110-121. PubMed ID: 30935913
[TBL] [Abstract][Full Text] [Related]
13. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies.
Bhaskar K; Anbu J; Ravichandiran V; Venkateswarlu V; Rao YM
Lipids Health Dis; 2009 Feb; 8():6. PubMed ID: 19243632
[TBL] [Abstract][Full Text] [Related]
14. Nanostructured lipid carriers (NLC) based controlled release topical gel of clobetasol propionate: design and in vivo characterization.
Nagaich U; Gulati N
Drug Deliv Transl Res; 2016 Jun; 6(3):289-98. PubMed ID: 27072979
[TBL] [Abstract][Full Text] [Related]
15. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake.
Tiwari R; Pathak K
Int J Pharm; 2011 Aug; 415(1-2):232-43. PubMed ID: 21640809
[TBL] [Abstract][Full Text] [Related]
16. Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: a comparative study.
Arora R; Katiyar SS; Kushwah V; Jain S
Expert Opin Drug Deliv; 2017 Feb; 14(2):165-177. PubMed ID: 27882780
[TBL] [Abstract][Full Text] [Related]
17. Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies.
Selvaraj BR; Sridhar SK; Kesavan BR; Palagati S
Pharm Nanotechnol; 2020; 8(6):452-470. PubMed ID: 32988361
[TBL] [Abstract][Full Text] [Related]
18. Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology.
Shadambikar G; Marathe S; Ji N; Almutairi M; Bandari S; Zhang F; Chougule M; Repka M
Int J Pharm X; 2021 Dec; 3():100074. PubMed ID: 33748741
[TBL] [Abstract][Full Text] [Related]
19. Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer.
Sherif AY; Harisa GI; Shahba AA; Alanazi FK; Qamar W
Molecules; 2023 Jan; 28(1):. PubMed ID: 36615641
[TBL] [Abstract][Full Text] [Related]
20. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments.
Soni K; Rizwanullah M; Kohli K
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):15-31. PubMed ID: 29183147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
